ArticleFrontiers in public health2024

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.

Zhanjing Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.